The European Commission has granted marketing authorization for Rekovelle (follitropin delta), a human recombinant follicle stimulating hormone (human rFSH), following a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October.
Privately-held Swiss firm Ferring Pharmaceuticals, the drug’s maker, says the approval is for the use of Rekovelle in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
Rekovelle is the first rFSH to be derived from a human cell line and is the first rFSH treatment to be administered with an individualised dosing regimen. Rekovelle’s individualized dosing regimen is based on a woman’s serum anti-Müllerian hormone (AMH) level and her body weight.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze